Formulation: A solid
Formal Name: N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-1H-indole-2-carboxamide
Purity: ≥98%
Formula Markup: C25H20N4O2
Formula Weight: 408,5
Shelf life (days): 1460
CAS Number: 103420-77-5
Notes: Devazepide is a nonpeptide antagonist of the cholecystokinin 1 (CCK1) receptor (Ki = 0.3 nM).{65732} It is selective for CCK1 over the CCK2 receptor (Ki = 342 nM). Devazepide inhibits CCK-8-induced amylase release in isolated dispersed rat pancreatic acini (IC50 = 25.4 nM). It reduces CCK-8-induced decreases in gastric emptying and food intake in rats (ED50s = 140 and 321 µg/kg, respectively), as well as CCK-8-induced contractions of colon and gall bladder in rabbits and cats, respectively (ED50s = 34 and 210 µg/kg, respectively).{65733} Devazepide (1 mg/kg) enhances morphine-induced increases in tail-flick latency and prevents the development of morphine tolerance, but does not affect morphine dependence, in rats.{65734} It also induces apoptosis and cell cycle arrest at the G1/G0 phase in, and inhibits the migration of, 5637 bladder cancer cells when used at a concentration of 25 µM.{65735}
English
Deutsch
